Status:

COMPLETED

A Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter in the Chinese Population

Lead Sponsor:

Becton, Dickinson and Company

Conditions:

Catheterization

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study is designed to evaluate the effectiveness and the safety of the PowerMeTM Midline Catheter in the Chinese population.

Detailed Description

This is a prospective, multi-center, open-label, randomized, controlled, non-inferiority clinical trial designed to evaluate the effectiveness and the safety of the PowerMeTM Midline Catheter compared...

Eligibility Criteria

Inclusion

  • ≥18 years of age;
  • Inpatient with a need for intravenous infusion for an expected period of more than 4 days but no more than 28 days;
  • The veins in the upper limbs is suitable for puncture and catheterization of both the investigational device and the control device;
  • Willing to provide written Informed Consent and complete the study per the protocol.

Exclusion

  • Coagulation disorder or active bleeding;
  • Skin injury, infection, or dermatosis at the site to be punctured;
  • History of radiotherapy, thrombosis, or vascular surgery; arteriovenous fistula or phlebitis history at the area and/or vein to be catheterized;
  • History of mental illness;
  • End stage renal disease requires vein protection;
  • Conditions with decreased venous flow in the extremity, such as lymphedema of the arm, etc.;
  • Infusions of vesicant or irritant drugs, hyperosmotic infusate (the osmotic pressure \>900mOsm/L in this study), parenteral nutrition, etc., which are not suitable for peripheral intravenous infusion (If other appropriate venous access is established for the aforementioned infusates, the patient may be enrolled).
  • The evaluation of the upper limb veins is Grade II, the evaluation grade is as following:
  • 0 Veins are obviously bulged on the skin surface. The veins are touchable, thick, straight, soft, elastic and fixed.
  • I Veins are relatively full and faintly touchable. The veins are less elastic or slide easily.
  • II Veins are not full or collapsed and untouchable. The veins are hard or sliding. Phlebitis.
  • Self-reported being pregnant or lactating;
  • Other conditions that the investigator considers improper for the study;
  • Participating in another study or already enrolled.

Key Trial Info

Start Date :

January 13 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2022

Estimated Enrollment :

256 Patients enrolled

Trial Details

Trial ID

NCT04719377

Start Date

January 13 2021

End Date

January 30 2022

Last Update

September 23 2022

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Hunan Cancer Hospital

Changsha, China

2

Shanghai First General Hospital

Shanghai, China, 200040

3

Shanghai Ninth People's Hospital

Shanghai, China

4

The First Affiliated Hospital of Soochow University

Suzhou, China